Drug intelligence / Profile preview

ZYN 001

Development stage: Preclinical
Lead developer: zyvran pharmaceuticals

Overview

ZYN 001 (P564X) is an investigational combination drug being developed by Zyvran Pharmaceuticals for the treatment of premature ejaculation (PE). Zyvran Pharmaceuticals focuses on developing combination therapies that target multiple physiological pathways simultaneously to optimize therapeutic efficacy and minimize side effects. As a combination drug, ZYN 001 is designed to address the complex neurological and physiological mechanisms underlying premature ejaculation.

Targets

CNR1 (Cannabinoid receptor 1)Δ9-THC (Delta-9-tetrahydrocannabinol)

Beyond the preview

Go deeper on ZYN 001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZYN 001.